Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 10/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263881 | 0.77 | FLT3 (0.47) | PKMDYRK1AGSK3AGSK3BPIK3CA | |
| Hydrochloric Acid SCHEMBL4032782 | 0.75 | FLT3 (0.46) | PKMDYRK1AGSK3AGSK3BPIK3CA | |
| SCHEMBL2261411 | 0.73 | PRMT5 (0.40) | GSK3AGSK3B | |
| SCHEMBL4034194 | 0.73 | PRMT5 (0.43) | — | |
| SCHEMBL5606241 | 0.68 | CYP1A2 (0.32) | — | |
| SCHEMBL4036874 | 0.68 | PRMT5 (0.44) | — | |
| SCHEMBL2261834 | 0.68 | CDK8 (0.50) | DYRK1A | |
| SCHEMBL2650737 | 0.67 | BACE1 (0.77) | BACE1CCNKCDK12PKMDYRK1A | |
| SCHEMBL2265404 | 0.67 | MKNK1 (0.50) | DYRK1AGSK3AGSK3B | |
| SCHEMBL3832037 | 0.66 | CYP1A2 (0.43) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7491716-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | BACE1 3313/4885CCNK 331/4885CDK12 251/4885 |
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | BACE1 3313/4885CCNK 331/4885CDK12 251/4885 |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | BACE1 3313/4885CCNK 331/4885CDK12 251/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | BACE1 3313/4885CCNK 331/4885CDK12 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.